In a more detailed study, Sung et al. demonstrated that treatment of the A2780 ovarian cancer cell line with OSF-2 led to the activation of the AKT-signaling pathway and as a result to CIS resistance. The gene discussed is AKT1; the disease is in situ carcinoma.